Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH5-HK H5N1 avian influenza vaccine
- Development stage
- Unknown
- Lead developer
- The Chemo-Sero-Therapeutic Research Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The CH5-HK H5N1 avian influenza vaccine is a monovalent stockpile vaccine candidate developed under the auspices of the Japan Agency for Medical Research and Development (AMED) Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA). It is specifically designed to provide protection against the H5N1 avian influenza virus, targeting the clade 2.3.4.4b lineage, which has demonstrated significant pandemic potential due to its widespread transmission in avian and mammalian populations. The vaccine contains 3.75 micrograms of hemagglutinin (HA) per 0.5 mL dose and is administered as a two-dose intramuscular regimen. It is currently undergoing Phase II clinical evaluation in Japan to determine its safety and immunogenicity profile in healthy adults, serving as a critical component of the national preparedness strategy for potential avian influenza outbreaks.
- Other names
- H5N1 avian influenza vaccine (clade 2.3.4.4b)
02
Targets
Hemagglutinin (H5) of A/Hong Kong/156/97 (H5N1) influenza virus (H5 HA)
Beyond the preview
Go deeper on CH5-HK H5N1 avian influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH5-HK H5N1 avian influenza vaccine.